Page last updated: 2024-11-06

sotalol hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sotalol hydrochloride is a beta blocker and class III antiarrhythmic agent used to treat atrial fibrillation, ventricular tachycardia, and other cardiac arrhythmias. It works by blocking the beta-adrenergic receptors in the heart, which slows the heart rate and reduces the force of heart contractions. Sotalol hydrochloride is also a potassium channel blocker, which helps to prolong the duration of the action potential in the heart. This effect helps to prevent the rapid firing of heart cells that can lead to arrhythmias. Sotalol hydrochloride is typically administered orally, but it can also be given intravenously. Its synthesis involves a multi-step process starting with a reaction of 2-amino-4-chlorophenol with 2-chloro-N-(2-chloroethyl)ethanamine, followed by a series of transformations and purifications. Sotalol hydrochloride has been studied extensively for its potential benefits in treating various cardiac arrhythmias. Research has focused on its efficacy, safety, and potential interactions with other medications. Its unique mechanism of action, combining beta-blockade and potassium channel blockade, has made it an important therapeutic option for patients with arrhythmias who may not respond well to other medications.'

sotalol hydrochloride : A hydrochloride salt that is the monohydrochloride of sotalol. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID66245
CHEMBL ID1700
CHEBI ID9207
SCHEMBL ID118761
MeSH IDM0020176

Synonyms (147)

Synonym
AC-3541
n-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide hydrochloride
sotalol.hcl
n-isopropyl-beta-(4-methanesulfonamidophenyl)ethanolamine hydrochloride
einecs 213-496-0
betapace
betapace af
4'-(1-hydroxy-2-isopropylaminoethyl)methanesulphonanilide hydrochloride
berlex
isopropylaminohydroxyethylmethanesulfonanilide hydrochloride
sotalol hydrochloride [usan]
sotalol hcl
methanesulfonanilide, 4'-(1-hydroxy-2-(isopropylamino)ethyl)-, monohydrochloride
sorine
sotalex
methanesulfonamide, n-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-, monohydrochloride
4-(2-isopropylamino-1-hydroxyaethyl)methanesulfonailid hydrochlorid [german]
4'-(1-hydroxy-2-(isopropylamino)ethyl)methanesulfonanilide monohydrochloride
EU-0101055
(+/-)-sotalol hydrochloride, >=98% (tlc), powder
mj-1999
sotalol monohydrochloride
cas-959-24-0
959-24-0
4'-[2-(isopropylamino)-1-hydroxyethyl]methanesulfonanilide monohydrochloride
[(isopropylamino)hydroxyethyl]methanesulfonanilide hydrochloride
4'-[1-hydroxy-2-(isopropylamino)ethyl]methanesulfonanilide hydrochloride
4-[2-(isopropylamine)-1-hydroxyethyl]methanesulfonanilide hydrochloride
n-isopropyl-.beta.-(4-methanesulfonamidophenyl)ethanolamine hydrochloride
4'-[2-(isopropylamino)-1-hydroxyethyl]methanesulfonanilide hydrochloride
mead johnson 1999
wln: ws1&mr dyq1my1&1 &gh
4'-[1-hydroxy-2-(isopropylamino)ethyl]methanesulfonanilide monohydrochloride
mj 1999 hydrochloride
sotacor
sotalol hydrochloride
nsc-337251
p-[1-hydroxy-2-(isopropylamino)ethyl]methanesulfonanilide hydrochloride
nsc337251
mj 1999
smr000326828
MLS000758296
MLS000859969
cpd000326828
sorine (tn)
sotalol hydrochloride (jan/usp)
D01026
betapace (tn)
NCGC00094337-02
(?)-sotalol hydrochloride
NCGC00094337-01
NCGC00094337-03
darob
MLS001401380
MLS002222318
( inverted question mark)-sotalol hydrochloride
S 0278
n-(4-[1-hydroxy-2-(isopropylamino)ethyl]phenyl)methanesulfonamide hydrochloride
n-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide hydrochloride
nsc-760358
dl-mj-1999
chebi:9207 ,
CHEMBL1700
HMS1571A13
A845501
n-[4-[1-oxidanyl-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide hydrochloride
nsc 337251
4-(2-isopropylamino-1-hydroxyaethyl)methanesulfonailid hydrochlorid
hec37c70xx ,
unii-hec37c70xx
nsc 760358
sotalol hydrochloride [usan:usp]
sotylize
tox21_200127
NCGC00257681-01
nsc760358
pharmakon1600-01506043
dtxcid801278
tox21_111267
dtxsid8021278 ,
n-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide hydrochloride
CCG-100907
sotalol (betapace)
BCP0726000245
FT-0603531
n-(2-hydroxy-2-{4-[(methylsulfonyl)amino]phenyl}ethyl)propan-2-aminium chloride
LP01055
(+/-)-sotalol hydrochloride
AKOS015888287
S2509
sotalol hydrochloride [mi]
sotalol hydrochloride [orange book]
sotalol hydrochloride [usp monograph]
4201-00-7
sotalol hydrochloride [jan]
sotylize component sotalol hydrochloride
methanesulfonamide, n-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-, hydrochloride (1:1)
sotalol hydrochloride [vandf]
sotalol hydrochloride [usp-rs]
sotalol hydrochloride [mart.]
sotalol hydrochloride component of sotylize
sotalol hydrochloride [ep monograph]
sotalol hydrochloride [who-dd]
CCG-213603
HY-B0437
sotalol (hydrochloride)
VIDRYROWYFWGSY-UHFFFAOYSA-N
SCHEMBL118761
NC00157
n-[4-[1-hydroxy-2-(isopropylamino)ethyl]phenyl]methanesulfonamide hydrochloride
tox21_501055
(y)-sotalol hydrochloride
NCGC00261740-01
Q-201730
n-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]methanesulfonamide hydrochloride
mfcd00242937
n-(4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}phenyl)methanesulfonamide hydrochloride
(+/-)-sotalol hydrochloride, analytical standard
sotalol hydrochloride, united states pharmacopeia (usp) reference standard
sotalol hydrochloride 1.0 mg/ml in methanol (as free base)
SR-01000076116-3
SR-01000076116-8
sr-01000076116
SR-01000076116-2
n-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide;hydrochloride
n-(4-(1-hydroxy-2-(isopropylamino)ethyl)phenyl)methanesulfonamide hydrochloride
SW197352-4
959-24-0 (hcl)
F21235
Q27108309
sotalol hydrochloride 100 microg/ml in acetonitrile
AS-13017
BCP02975
sotalol, hcl
sotalol hydrochloride- bio-x
BS164418
n-(2-hydroxy-2-(4-((methylsulfonyl)amino)phenyl)ethyl)propan-2-aminium chloride
sotalol hydrochloride (usan:usp)
4-((rs)-1-hydroxy-2-(isopropylamino)ethyl)methanesulfonanilide monohydrochloride
n-(4-(1-hydroxy-2-(propan-2-ylamino)ethyl)phenyl)methanesulfonamide hydrochloride
sotalol hydrochloride (usp-rs)
sotalol hydrochloride tablets af
sotalol hydrochloride tables af
sotalol hydrochlorideaf
sotalol hydrochloride (ep monograph)
sotalol hydrochloride (usp monograph)
sotalol hydrochloride (mart.)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
beta-adrenergic antagonistAn agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00140.003245.467312,589.2998AID2517
acetylcholinesteraseHomo sapiens (human)Potency40.33860.002541.796015,848.9004AID1347395
GLS proteinHomo sapiens (human)Potency17.78280.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency33.49830.000811.382244.6684AID686978
AR proteinHomo sapiens (human)Potency44.88170.000221.22318,912.5098AID1259243; AID1259381
progesterone receptorHomo sapiens (human)Potency61.75280.000417.946075.1148AID1346784
67.9K proteinVaccinia virusPotency0.39810.00018.4406100.0000AID720580
alpha-galactosidaseHomo sapiens (human)Potency0.17784.466818.391635.4813AID2107
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.89130.540617.639296.1227AID2364; AID2528
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency10.26630.01789.637444.6684AID588834
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency31.62280.794321.275750.1187AID624246
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency8.42180.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)IC50 (µMol)7.20000.00020.93267.2000AID41152
Beta-1 adrenergic receptorHomo sapiens (human)IC50 (µMol)7.20000.00021.46819.0000AID41152
Beta-3 adrenergic receptorHomo sapiens (human)IC50 (µMol)7.20000.00233.24158.0600AID41152
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, BCL-2-RELATED PROTEIN A1Homo sapiens (human)EC50 (µMol)350.00008.0570121.1218338.0000AID2765
bcl-2-like protein 11 isoform 1Homo sapiens (human)EC50 (µMol)350.00008.0570121.1218338.0000AID2765
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (98)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID41152Concentration effective against displacing [3H]dihydroalprenolol from beta adrenergic receptor from canine ventricular tissue1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
AID62784Conduction time from Q wave to T wave of lead II electrocardiogram was tested in dogs at a dose of 3.0 mg/kg through intravenous administration. (baseline value- 352+/-7)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62649Compound was tested in vivo in dogs at a dose of 3.0 mg/kg through intravenous route and time at which nonsustained ventricular arrhythmias were induced was recorded.(Base line value-1)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62798Conduction time from the atrium to His bundle was tested in dogs at a dose of 3.0 mg/kg through intravenous administration. (baseline value 73+/-3 )1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62797Conduction time from the atrium to His bundle was tested in dogs at a dose of 10.0 mg/kg through intravenous administration. (baseline value- 73+/-3 )1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62648Compound was tested in vivo in dogs at a dose of 3.0 mg/kg through intravenous route and time at which conduction block at the atrioventricular node prevented atrial pacing was recorded.(Base line value-0)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62658Conduction time for ventricular refractory period of the first premature stimulus was tested in dogs at a dose of 0.1 mg/kg through intravenous administration; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62791Conduction time from the His bundle to the onset of ventricular depolarizations was tested in dogs at a dose of 3.0 mg/kg through intravenous administration. (baseline value- 17+/-1 )1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62639Compound was tested in vivo in dogs at a dose of 1.0 mg/kg through intravenous route and time at which ventricular arrhythmias were not indicible was recorded.(Base line value-5)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID165521Tested for conduction time measured at a pacing rate of 1 Hz in vitro with rabbit heart tissue preparations.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID165584Compound was tested for conduction time measured at a pacing rate of 3 Hz in vitro with rabbit heart tissue preparations; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62789Conduction time from the His bundle to the onset of ventricular depolarizations was tested in dogs at a dose of 1.0 mg/kg through intravenous administration. (baseline value- 17+/-1 )1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62781Conduction time from Q wave to T wave of lead II electrocardiogram was tested in dogs at a dose of 0.3 mg/kg through intravenous administration; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID1143339Inhibition of Cacl2-Ach-induced atrial fibrillation Sprague-Dawley rat model assessed as reduction in duration of atrial fibrillation at 2.5 mg/kg, ip during day 1 to day 32014European journal of medicinal chemistry, Jun-23, Volume: 81Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I).
AID62665Conduction time for ventricular refractory period of the second premature stimulus was tested in dogs at a dose of 0.1 mg/kg through intravenous administration; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62783Conduction time from Q wave to T wave of lead II electrocardiogram was tested in dogs at a dose of 10 mg/kg through intravenous administration. (baseline value- 352+/-7)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62662Conduction time for ventricular refractory period of the first premature stimulus was tested in dogs at a dose of 10.0 mg/kg through intravenous administration. (baseline value- 137+/-4)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62525Compound was tested in vivo in dogs at a dose of 1.0 mg/kg through intravenous route and time at which conduction block at the atrioventricular node prevented atrial pacing was recorded.(Base line value-0)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID62782Conduction time from Q wave to T wave of lead II electrocardiogram was tested in dogs at a dose of 1.0 mg/kg through intravenous administration. (baseline value- 352+/-7)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62404In vivo antiarrhythmic efficacy in a programmed electrical stimulation (PES) model of mongrel dogs expressed as minimum effect dose (iv) at iv dose range of 0.1-30 mg/kg.1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
AID62502Compound was tested in vivo in dogs at a dose of 0.1 mg/kg through intravenous route and time at which nonsustained ventricular arrhythmias were induced was recorded; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62505Compound was tested in vivo in dogs at a dose of 0.1 mg/kg through intravenous route and time at which sustained ventricular arrhythmias were induced was recorded; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62521Compound was tested in vivo in dogs at a dose of 0.3 mg/kg through intravenous route and time at which ventricular arrhythmias were not indicible was recorded; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62795Conduction time from the atrium to His bundle was tested in dogs at a dose of 0.3 mg/kg through intravenous administration; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62670Conduction time for ventricular refractory period of the second premature stimulus was tested in dogs at a dose of 3.0 mg/kg through intravenous administration. (baseline value- 123+/-4)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62246Maximum observed change in ADP95 from control value was determined in isolated canine cardiac uM1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
AID62796Conduction time from the atrium to His bundle was tested in dogs at a dose of 1.0 mg/kg through intravenous administration. (baseline value- 73+/-3 )1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID61124In vivo intraduodenal activity in mongrel dogs was assessed by percent change in heart rate at active dose of 10 mg/kg, administered intradermally1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
AID62515Compound was tested in vivo in dogs at a dose of 0.3 mg/kg through intravenous route and time at which nonsustained ventricular arrhythmias were induced was recorded; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID1143343Inhibition of Cacl2-Ach-induced atrial fibrillation Sprague-Dawley rat model assessed as reduction in duration of atrial effective refractory period at 2.5 mg/kg, ip2014European journal of medicinal chemistry, Jun-23, Volume: 81Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I).
AID62248Maximum observed change in FRP from control was determined in isolated canine ventricular muscle fibers at a concentration of 100 uM1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
AID62660Conduction time for ventricular refractory period of the first premature stimulus was tested in dogs at a dose of 0.3 mg/kg through intravenous administration; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62661Conduction time for ventricular refractory period of the first premature stimulus was tested in dogs at a dose of 1.0 mg/kg through intravenous administration. (baseline value- 137+/-4)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62663Conduction time for ventricular refractory period of the first premature stimulus was tested in dogs at a dose of 3.0 mg/kg through intravenous administration. (baseline value- 137+/-4)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID167477Tested for effective refractory period measured at a pacing rate of 1 Hz in vitro with rabbit heart tissue preparations.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID167699Tested for rate automaticity measured in beats per minute from unpaced right atria of rabbit heart.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62644Compound was tested in vivo in dogs at a dose of 10.0 mg/kg through intravenous route and time at which nonsustained ventricular arrhythmias were induced was recorded.(Base line value-1)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID57343Concentration that causes 20% increase in ADP95 (action potential duration at 95% repolarization) was determined on isolated canine cardiac Purkinje fibers;range is 11.2-18.61987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
AID62668Conduction time for ventricular refractory period of the second premature stimulus was tested in dogs at a dose of 1.0 mg/kg through intravenous administration. (baseline value- 123+/-4)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62654Compound was tested in vivo in dogs at a dose of 3.0 mg/kg through intravenous route and time at which ventricular arrhythmias were not indicible was recorded.(Base line value-5)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID1143341Inhibition of Cacl2-Ach-induced atrial fibrillation Sprague-Dawley rat model assessed as reduction in duration of atrial fibrillation at 2.5 mg/kg, ip during day 4 to day 72014European journal of medicinal chemistry, Jun-23, Volume: 81Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I).
AID62512Compound was tested in vivo in dogs at a dose of 0.3 mg/kg through intravenous route and time at which conduction block at the atrioventricular node prevented atrial pacing was recorded.(Base line value-0)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62667Conduction time for ventricular refractory period of the second premature stimulus was tested in dogs at a dose of 0.3 mg/kg through intravenous administration; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62530Compound was tested in vivo in dogs at a dose of 1.0 mg/kg through intravenous route and time at which sustained ventricular arrhythmias were induced was recorded.(Base line value-2)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID61123In vivo intraduodenal activity in mongrel dogs was assessed by percent change in blood pressure at active dose of 10 mg/kg, administered intradermally1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
AID60108In vivo antiarrhythmic efficacy in a programmed electrical stimulation (PES) model of mongrel dogs reported as number of animals effective at dose range of 0.1-30 mg/kg. 1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
AID62643Compound was tested in vivo in dogs at a dose of 10.0 mg/kg through intravenous route and time at which conduction block at the atrioventricular node prevented atrial pacing was recorded.(Base line value-0)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62669Conduction time for ventricular refractory period of the second premature stimulus was tested in dogs at a dose of 10 mg/kg through intravenous administration. (baseline value- 123+/-4)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62518Compound was tested in vivo in dogs at a dose of 0.3 mg/kg through intravenous route and time at which sustained ventricular arrhythmias were induced was recorded; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62526Compound was tested in vivo in dogs at a dose of 1.0 mg/kg through intravenous route and time at which nonsustained ventricular arrhythmias were induced was recorded.(Base line value-0)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62646Compound was tested in vivo in dogs at a dose of 10.0 mg/kg through intravenous route and time at which ventricular fibrillation was induced was recorded.(Base line value-6)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62790Conduction time from the His bundle to the onset of ventricular depolarizations was tested in dogs at a dose of 10.0 mg/kg through intravenous administration. (baseline value- 17+/-1 )1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62394Compound was tested in vivo in dogs at a dose of 0.1 mg/kg through intravenous route and time at which conduction block at the atrioventricular node prevented atrial pacing was recorded.(Base line value-0)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62656Compound was tested in vivo in dogs at a dose of 3.0 mg/kg through intravenous route and time at which ventricular fibrillation was induced was recorded.(Base line value-6)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62641Compound was tested in vivo in dogs at a dose of 1.0 mg/kg through intravenous route and time at which ventricular fibrillation was induced was recorded.(Base line value-3)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62511Compound was tested in vivo in dogs at a dose of 0.1 mg/kg through intravenous route and time at which ventricular fibrillation was induced was recorded; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62788Conduction time from the His bundle to the onset of ventricular depolarizations was tested in dogs at a dose of 0.3 mg/kg through intravenous administration; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62508Compound was tested in vivo in dogs at a dose of 0.1 mg/kg through intravenous route and time at which ventricular arrhythmias were not indicible was recorded; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62524Compound was tested in vivo in dogs at a dose of 0.3 mg/kg through intravenous route and time at which ventricular fibrillation was induced was recorded; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID167622Tested for force of contraction measured in mg at a pacing rate of 2 Hz in vitro with rabbit heart tissue preparations.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62780Conduction time from Q wave to T wave of lead II electrocardiogram was tested in dogs at a dose of 0.1 mg/kg through intravenous administration; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID61121In vivo antiarrhythmic efficacy in a PES model of mongrel dog expressed as percent change in blood pressure at iv dose range of 0.1-30 mg/kg.1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
AID62647Compound was tested in vivo in dogs at a dose of 10 mg/kg through intravenous route and time at which ventricular arrhythmias were not indicible was recorded.(Base line value-5)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62645Compound was tested in vivo in dogs at a dose of 10.0 mg/kg through intravenous route and time at which sustained ventricular arrhythmias were induced was recorded.(Base line value-2)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62793Conduction time from the atrium to His bundle was tested in dogs at a dose of 0.1 mg/kg through intravenous administration; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID62786Conduction time from the His bundle to the onset of ventricular depolarizations was tested in dogs at a dose of 0.1 mg/kg through intravenous administration; Not tested1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID167478Tested for effective refractory period measured at a pacing rate of 3 Hz in vitro with rabbit heart tissue preparations.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID57347Concentration that causes 20% increase in functional refractory period (FRP) was determined on isolated canine ventricular muscle fibers;range is 3.7-1621987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
AID62652Compound was tested in vivo in dogs at a dose of 3.0 mg/kg through intravenous route and time at which sustained ventricular arrhythmias were induced was recorded.(Base line value-2)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity.
AID61122In vivo antiarrhythmic efficacy in a PES model of mongrel dog expressed as percent change in heart rate at iv dose range of 0.1-30 mg/kg.1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.00)18.7374
1990's1 (5.00)18.2507
2000's2 (10.00)29.6817
2010's11 (55.00)24.3611
2020's5 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.90 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index80.45 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]